FDAnews Drug Daily Bulletin

ZABECOR PHARMACEUTICAL CO. LICENSES ITS ANTI-INFLAMMATORY SIRNA TECHNOLOGY TO ACUITY PHARMACEUTICALS FOR OPHTHALMIC USES

May 1, 2006
A A

ZaBeCor Pharmaceutical Co., a privately-held company focused on the development and commercialization of patented drug technology centered on inflammation, today announced that it has entered into a license option agreement with Acuity Pharmaceuticals, a clinical stage, product-focused ophthalmic pharmaceutical company, with Acuity to receive exclusivity for ophthalmologic uses of ZaBeCor's lead drug candidate Excellair. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-28-2006/0004350067&EDATE=)